Search

Your search keyword '"Díaz, Luis A."' showing total 83 results

Search Constraints

Start Over You searched for: Author "Díaz, Luis A." Remove constraint Author: "Díaz, Luis A." Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
83 results on '"Díaz, Luis A."'

Search Results

3. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

4. Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

5. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

6. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients

8. MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma

11. Evaluation of dietary single probiotic isolates and probiotic multistrain consortia in growth performance, gut histology, gut microbiota, immune regulation, and infection resistance of Nile tilapia, Oreochromis niloticus, shows superior monostrain performance

13. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

15. Vancomycin-resistant Enterococcus faecium: admission prevalence, sequence types and risk factors–a cross-sectional study in seven German university hospitals from 2014 to 2018

18. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas

19. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

21. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

24. Increasing numbers and complexity of Staphylococcus aureus bloodstream infection—14 years of prospective evaluation at a German tertiary care centre with multi-centre validation of findings

40. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

50. Global multi-stakeholder endorsement of the MAFLD definition

Catalog

Books, media, physical & digital resources